Doctors caught in the middle of an escalating battle over U.S. drug prices are losing influence over their patients’ treatment even as they gain an opportunity to treat more people more affordably.
The trade-off physicians are facing came into stark relief today, when the biggest U.S. drug-benefit manager rejected coverage of Gilead Sciences Inc.’s $1,000-a-pill hepatitis C drug in favor of a cheaper therapy from AbbVie Inc.
